Immunoadsorption therapy in dilated cardiomyopathy

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 2, 2015, Pages 145-152

  Felix, Stephan B ^a,b   Beug, Daniel ^a   Dörr, Marcus ^a,b  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

cardiac antibodies; dilated cardiomyopathy; humoral immune system; immunoadsorption; immunomodulation; myocardial inflammation

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; BETA 1 ADRENERGIC RECEPTOR; CYCLOSPORIN; FC RECEPTOR; HEART ANTIBODY; HEART ANTIGEN; IMMUNOGLOBULIN; PLACEBO; PREDNISONE;

ANTIVIRAL THERAPY; AUTOIMMUNITY; CELLULAR IMMUNITY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DISEASE COURSE; GENETIC PREDISPOSITION; HEART FAILURE; HEART FUNCTION; HEART INDEX; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HUMAN; HUMORAL IMMUNITY; IMMUNOADSORPTION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MOLECULAR MIMICRY; MYOCARDITIS; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC VASCULAR RESISTANCE; TREATMENT RESPONSE; BLOOD; CARDIOMYOPATHY, DILATED; IMMUNOLOGY; PROCEDURES;

AUTOANTIBODIES; CARDIOMYOPATHY, DILATED; HEART FAILURE; HUMANS; IMMUNITY, HUMORAL; IMMUNOTHERAPY; MYOCARDITIS;

EID: 84921457655     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.990385     Document Type: Review

References (73)

1. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113:1807-16
2. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636-48; 2648a-2648d.
3. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996;93: 841-2
4. Dec GW Jr, Palacios IF, Fallon JT, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med 1985;312:885-90
5. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000;343:1388-98
6. Cooper LT Jr. Myocarditis. N Engl J Med 2009;360:1526-38
7. Felker GM, Hu W, Hare JM, et al. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. Medicine (Baltimore) 1999;78:270-83
8. Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005;111:887-93.
9. Bowles NE, Richardson PJ, Olsen EG, Archard LC. Detection of Coxsackie-Bvirus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1986;1:1120-3
10. Kandolf R, Ameis D, Kirschner P, et al. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. Proc Natl Acad Sci USA 1987;84:6272-6
11. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation 2001;104:1076-82.
12. Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation 2006;113:876-90.
13. Pauschinger M, Bowles NE, Fuentes-Garcia FJ, et al. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 1999;99:1348-54
14. Kühl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005;112:1965-70
15. Kühl U, Noutsias M, Schultheiss HP. Immunohistochemistry in dilated cardiomyopathy. Eur Heart J 1995; 16(Suppl O):100-6
16. Noutsias M, Seeberg B, Schultheiss HP, Kühl U. Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 1999;99:2124-31
17. Wojnicz R, Nowalany-Kozielska E, Wodniecki J, et al. Immunohistological diagnosis of myocarditis. Potential role of sarcolemmal induction of the MHC and ICAM-1 in the detection of autoimmune mediated myocyte injury. Eur Heart J 1998;19:1564-72
18. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-6
19. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995;333:269-75
20. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008;118:639-48
21. Eriksson U, Ricci R, Hunziker L, et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 2003;9:1484-90
22. Rose NR. Viral damage or 'molecular mimicry'-placing the blame in myocarditis. Nat Med 2000;6:631-2
23. Schultheiss HP, Kühl U, Janda I, et al. Antibody-mediated enhancement of calcium permeability in cardiac myocytes. J Exp Med 1988;168:2105-19
24. Caforio AL, Grazzini M, Mann JM, et al. Identification of alpha-and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 1992;85:1734-42
25. Wallukat G, Wollenberger A, Morwinski R, Pitschner HF. Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 1995;27:397-406
26. Fu LX, Magnusson Y, Bergh CH, et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1993;91: 1964-8
27. Baba A, Yoshikawa T, Ogawa S. Autoantibodies produced against sarcolemmal Na-K-ATPase: possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J Am Coll Cardiol 2002;40:1153-9
28. Lauer B, Schannwell M, Kühl U, et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000;35:11-18
29. Felix SB, Staudt A, Landsberger M, et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002;39:646-52
30. Li Y, Heuser JS, Cunningham LC, et al. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 2006;177:8234-40
31. Fu ML, Schulze W, Wallukat G, et al. A synthetic peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyocytes by active immunization after 6 months in rabbits. Clin Immunol Immunopathol 1996;78:203-7
32. Matsui S, Fu ML, Katsuda S, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 1997;29:641-55
33. Jahns R, Boivin V, Hein L, et al. Direct evidence for a beta 1-adrenergic receptordirected autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004;113:1419-29
34. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;291:319-22
35. Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003;9: 1477-83
36. Göser S, Andrassy M, Buss SJ, et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 2006;114: 1693-702.
37. Kaya Z, Leib C, Katus HA. Autoantibodies in heart failure and cardiac dysfunction. Circ Res 2012;110:145-58
38. Caforio AL, Mahon NG, Baig MK, et al. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 2007;115:76-83
39. Jhund PS, Macintyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009;119:515-23
40. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847
41. Kühl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003;107:2793-8
42. Kühl U, Lassner D, von Schlippenbach J, et al. Interferon-Beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol 2012;60:1295-6
43. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 1987;18:619-24
44. Parrillo JE, Cunnion RE, Epstein SE, et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989;321:1061-8
45. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001;104:39-45
46. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009;30:1995-2002
47. Tha-In T, Bayry J, Metselaar HJ, et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008;29:608-15
48. Tjon AS, van Gent R, Jaadar H, et al. Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production. J Immunol 2014;192: 5625-34
49. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001;103:220-5
50. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001;103: 2254-9
51. Bygren P, Freiburghaus C, Lindholm T, et al. Goodpasture's syndrome treated with staphylococcal protein A immunoadsorption. Lancet 1985;2: 1295-6
52. Palmer A, Gjorstrup P, Severn A, et al. Treatment of systemic lupus erythematosus by extracorporeal immunoadsorption. Lancet 1988;2:272
53. Roifman CM, Schaffer FM, Wachsmuth SE, et al. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 1987;258:513-15
54. Felix SB, Staudt A. Immunoadsorption as treatment option in dilated cardiomyopathy. Autoimmunity 2008;41:484-9
55. Dörffel WV, Felix SB, Wallukat G, et al. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 1997;95: 1994-7
56. Felix SB, Staudt A, Dörffel WV, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 2000;35:1590-8.
57. Staudt A, Schaper F, Stangl V, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 2001;103:2681-6.
58. Bulut D, Scheeler M, Wichmann T, et al. Effect of protein A immunoadsorption on T cell activation in patients with inflammatory dilated cardiomyopathy. Clin Res Cardiol 2010;99:633-8
59. Bulut D, Creutzenberg G, Mugge A. The number of regulatory T cells correlates with hemodynamic improvement in patients with inflammatory dilated cardiomyopathy after immunoadsorption therapy. Scand J Immunol 2013;77:54-61
60. Staudt A, Staudt Y, Dörr M, et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy. J Am Coll Cardiol 2004;44:829-36
61. Staudt A, Bohm M, Knebel F, et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 2002;106: 2448-53
62. Staudt A, Dörr M, Staudt Y, et al. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J 2005;150:729-36
63. Staudt A, Eichler P, Trimpert C, et al. Fc (gamma) receptors IIa on cardiomyocytes and their potential functional relevance in dilated cardiomyopathy. J Am Coll Cardiol 2007;49:1684-92
64. Muller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000;101:385-91
65. Staudt A, Hummel A, Ruppert J, et al. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am Heart J 2006;152:712; e1-6
66. Staudt A, Herda LR, Trimpert C, et al. Fcgamma-receptor IIa polymorphism and the role of immunoadsorption in cardiac dysfunction in patients with dilated cardiomyopathy. Clin Pharmacol Ther 2010;87:452-8
67. Doesch AO, Mueller S, Konstandin M, et al. Effects of protein A immunoadsorption in patients with chronic dilated cardiomyopathy. J Clin Apher 2010;25:315-22
68. Pokrovsky SN, Ezhov MV, Safarova MS, et al. Ig apheresis for the treatment of severe DCM patients. Atheroscler Suppl 2013;14: 213-18
69. Herda LR, Trimpert C, Nauke U, et al. Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy. Am Heart J 2010;159:809-16
70. Bulut D, Scheeler M, Niedballa LM, et al. Effects of immunoadsorption on endothelial function, circulating endothelial progenitor cells and circulating microparticles in patients with inflammatory dilated cardiomyopathy. Clin Res Cardiol 2011;100:603-10
71. Dandel M, Wallukat G, Englert A, et al. Long-term benefits of immunoadsorption in beta(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. Eur J Heart Fail 2012;14: 1374-88
72. Ameling S, Herda LR, Hammer E, et al. Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy. Eur Heart J 2013;34:666-75
73. Multicenter study of immunoadsorption in dilated cardiomyopathy. Available from: http://clinicaltrials.gov/show/NCT00558584